NDAORALCAPSULEPriority Review
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COGNEX (tacrine hydrochloride) is an oral small-molecule cholinesterase inhibitor approved in 1993 for Alzheimer's disease. It works by increasing acetylcholine levels in the brain to improve cognitive function. The drug represents one of the earliest pharmacologic interventions for cognitive decline in dementia.
LOE Approaching
With loss of exclusivity approaching, the brand team is likely in transition or contraction mode, limiting long-term career growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, career opportunities on COGNEX are severely limited. Working on this product offers minimal growth potential and likely involves managing decline rather than driving expansion.
Brand ManagerProduct Manager
Worked on COGNEX at Shionogi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.